Coherus Oncology (CHRS) Other Non Operating Income (2013 - 2026)

Coherus Oncology has disclosed Other Non Operating Income across 14 years of filings, most recently posting $1.4 million for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $1.4 million, up 649.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.2 million (down 65.71% YoY), and the FY2025 annual result was $7.0 million, down 8.03% from the prior year.
• Other Non Operating Income came in at $1.4 million for Q1 2026 at Coherus Oncology, down from $1.8 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $20.3 million in Q4 2024 to a low of -$8.0 million in Q4 2022.
• The 5-year median for Other Non Operating Income is $1.6 million (2023), against an average of $2.0 million.
• Across the five-year window, Other Non Operating Income slumped 1987.27% in 2022 and soared 15800.0% in 2024, its largest moves.
• Coherus Oncology's Other Non Operating Income stood at -$8.0 million in 2022, then surged by 98.39% to -$129000.0 in 2023, then jumped by 15800.0% to $20.3 million in 2024, then slumped by 91.2% to $1.8 million in 2025, then declined by 21.32% to $1.4 million in 2026.
• The last three Other Non Operating Income figures came in at $1.4 million (Q1 2026), $1.8 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.